Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Martín-Soberón MC"'
Autor:
Cantero D, de Velasco G, Hernández Laín A, Martín-Soberón Mc, Hilario A, Sepúlveda Sánchez Jm, Rodríguez, Ruano Y, Ó. Toldos, Antonio Ramos, Pérez Núñez A
Publikováno v:
Biomedical Journal of Scientific & Technical Research. 33
We present a 36-year-old female affected of ulcerative proctitis treated with rectal mesalazine and with no other pathological previous history...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8021fccbeafbaa6832c3a5ad97b6723
https://doi.org/10.26717/bjstr.2021.33.005472
https://doi.org/10.26717/bjstr.2021.33.005472
Autor:
Vieito M; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Universidad Autonoma de Barcelona, Barcelona, Spain., Simonelli M; Department of Biomedical Sciences, Humanitas University, Milan, Italy.; IRCCS Humanitas Research Hospital, Milan, Italy., de Vos F; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands., Moreno V; START Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain., Geurts M; Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Lorenzi E; IRCCS Humanitas Research Hospital, Milan, Italy., Macchini M; Department of Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy., van den Bent MJ; Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Del Conte G; Department of Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy., de Jonge M; Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Martín-Soberón MC; Neuro-Oncology Unit, Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain., Amoroso B; Centre for Innovation and Translational Research Europe, A Bristol Myers Squibb Company, Seville, Spain., Sanchez-Perez T; Centre for Innovation and Translational Research Europe, A Bristol Myers Squibb Company, Seville, Spain., Zuraek M; Bristol Myers Squibb, San Francisco, CA, USA., Hanna B; Bristol Myers Squibb, Princeton, NJ, USA., Aronchik I; Bristol Myers Squibb, San Francisco, CA, USA., Filvaroff E; Bristol Myers Squibb, San Francisco, CA, USA., Chang H; Bristol Myers Squibb, San Francisco, CA, USA., Mendez C; Centre for Innovation and Translational Research Europe, A Bristol Myers Squibb Company, Seville, Spain., Arias Parro M; Bristol Myers Squibb, Boudry, Switzerland., Wei X; Bristol Myers Squibb, Princeton, NJ, USA., Nikolova Z; Centre for Innovation and Translational Research Europe, A Bristol Myers Squibb Company, Seville, Spain., Sepulveda JM; Hospital Universitario 12 de Octubre, Madrid, Spain.
Publikováno v:
Neuro-oncology advances [Neurooncol Adv] 2022 Oct 28; Vol. 4 (1), pp. vdac146. Date of Electronic Publication: 2022 Oct 28 (Print Publication: 2022).
Autor:
Martínez-García M; Medical Oncology Department, Hospital del Mar, 08003 Barcelona, Spain.; Medical Oncology Department, Centro Integral Oncológico Clara Campal HM Delfos, 08023 Barcelona, Spain.; Cancer Research Program, Instituto Hospital del Mar de Investigaciones Médicas, 08003 Barcelona, Spain., Velasco G; Biochemistry and Molecular Biology Department, School of Biology, Complutense University, 28040 Madrid, Spain.; Instituto de Investigación Sanitaria San Carlos (IdISSC), 28040 Madrid, Spain., Pineda E; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Medical Oncology Department, Hospital Clínic, 08036 Barcelona, Spain., Gil-Gil M; Medical Oncology Department, Institut Català d'Oncologia L'Hospitalet, 08908 L'Hospitalet de Llobregat, Spain., Alameda F; Pathology Department, Hospital del Mar, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain., Capellades J; Radiology Department, Hospital del Mar, 08003 Barcelona, Spain., Martín-Soberón MC; Medical Oncology Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain., López-Valero I; Biochemistry and Molecular Biology Department, School of Biology, Complutense University, 28040 Madrid, Spain., Tovar Ambel E; Biochemistry and Molecular Biology Department, School of Biology, Complutense University, 28040 Madrid, Spain., Foro P; Radiation Oncology Department, Hospital del Mar, 08003 Barcelona, Spain., Taus Á; Medical Oncology Department, Hospital del Mar, 08003 Barcelona, Spain.; Cancer Research Program, Instituto Hospital del Mar de Investigaciones Médicas, 08003 Barcelona, Spain., Arumi M; Medical Oncology Department, Institut Català d'Oncologia L'Hospitalet, 08908 L'Hospitalet de Llobregat, Spain., Hernández-Laín A; Pathology Department (Neuropathology), Hospital 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain., Sepúlveda-Sánchez JM; Medical Oncology Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.
Publikováno v:
Cancers [Cancers (Basel)] 2022 May 12; Vol. 14 (10). Date of Electronic Publication: 2022 May 12.
Autor:
Martín-Soberón MC; Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain. mcms.207@gmail.com., Ruiz S; Nuclear Medicine Department, University Hospital 12 de Octubre, Madrid, Spain., De Velasco G; Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain., Yarza R; Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain., Carretero A; Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain., Castellano D; Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain., Sepúlveda-Sánchez JM; Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain.
Publikováno v:
Journal of medical case reports [J Med Case Rep] 2021 Mar 02; Vol. 15 (1), pp. 109. Date of Electronic Publication: 2021 Mar 02.
Autor:
Cejalvo T; Instituto de investigación I+12, Hospital 12 de Octubre, 28041 Madrid, Spain.; Neurooncology Unit, Instituto de Salud Carlos III-UFIEC, 28220 Madrid, Spain., Gargini R; Neurooncology Unit, Instituto de Salud Carlos III-UFIEC, 28220 Madrid, Spain., Segura-Collar B; Neurooncology Unit, Instituto de Salud Carlos III-UFIEC, 28220 Madrid, Spain., Mata-Martínez P; Neurooncology Unit, Instituto de Salud Carlos III-UFIEC, 28220 Madrid, Spain., Herranz B; Neurooncology Unit, Instituto de Salud Carlos III-UFIEC, 28220 Madrid, Spain.; Facultad de Medicina de la Universidad Francisco de Vitoria, 28223 Madrid, Spain., Cantero D; Instituto de investigación I+12, Hospital 12 de Octubre, 28041 Madrid, Spain., Ruano Y; Instituto de investigación I+12, Hospital 12 de Octubre, 28041 Madrid, Spain., García-Pérez D; Dto. Neurocirugía, Hospital 12 de Octubre, Universidad Complutense, 28041 Madrid, Spain., Pérez-Núñez Á; Dto. Neurocirugía, Hospital 12 de Octubre, Universidad Complutense, 28041 Madrid, Spain., Ramos A; Dto. Radiología, Hospital 12 de Octubre, Universidad Complutense, 28041 Madrid, Spain., Hernández-Laín A; Instituto de investigación I+12, Hospital 12 de Octubre, 28041 Madrid, Spain., Martín-Soberón MC; Instituto de investigación I+12, Hospital 12 de Octubre, 28041 Madrid, Spain., Sánchez-Gómez P; Neurooncology Unit, Instituto de Salud Carlos III-UFIEC, 28220 Madrid, Spain., Sepúlveda-Sánchez JM; Instituto de investigación I+12, Hospital 12 de Octubre, 28041 Madrid, Spain.
Publikováno v:
Cancers [Cancers (Basel)] 2020 Nov 02; Vol. 12 (11). Date of Electronic Publication: 2020 Nov 02.
Autor:
Sepúlveda-Sánchez JM; Medical Oncology Department, Hospital Universitario, 12 de Octubre, Avda. Andalucía s/n, 28041, Madrid, Spain. sepulvedasanchez@seom.org., Gil-Gil M; Medical Oncology Department, Institut Català d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain., Alonso-García M; Medical Oncology Department, Hospital Universitario Virgen del Rocío, Seville, Spain., Vaz Salgado MÁ; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain., Vicente E; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain., Mesía Barroso C; Medical Oncology Department, Institut Català d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain., Rodríguez Sánchez Á; Medical Oncology Department, Hospital Universitario de León, León, Spain., Durán G; Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain., De Las Peñas R; Medical Oncology Department, Consorcio Hospitalario Provincial de Castellón, Castellón, Spain., Muñoz-Langa J; Medical Oncology Department, Hospital Universitario y Policlínico La Fe, Valencia, Spain., Velasco G; Chemical Sciences Faculty, Universidad Complutense de Madrid, Madrid, Spain., Hernández-Laín A; Department of Pathology (Neuropathology), Instituto de Investigaciones Biomédicas I+12, Hospital Universitario, 12 de Octubre, Madrid, Spain., Hilario A; Radiology Department, Universitary Hospital, 12 de Octubre, Madrid, Spain., Navarro Martín M; Medical Oncology Department, Hospital Universitario de Salamanca, Salamanca, Spain., Benavides M; Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain., Oleaga L; Radiology Department, Hospital Clínic Barcelona, Barcelona, Spain., Cantero Montenegro D; Neurooncology (Molecular Biology) Department, Hospital Universitario, 12 de Octubre, Madrid, Spain., Ruano Y; Molecular Pathology Unit, Hospital Universitario 12 de Octubre Research Institute, Madrid, Spain., Sánchez-Gómez P; Neurooncology Unit, Instituto de Salud Carlos III-UFIEC, Madrid, Spain., Martín-Soberón MC; Medical Oncology Department, Hospital Universitario, 12 de Octubre, Avda. Andalucía s/n, 28041, Madrid, Spain., Morales-Llombart R; MFAR Clinical Research, Barcelona, Spain., Pachón V; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain., Pineda E; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Medical Oncology Department, Hospital Clínic, Barcelona, Spain.
Publikováno v:
Targeted oncology [Target Oncol] 2020 Oct; Vol. 15 (5), pp. 613-622.